Summit Therapeutics Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone Q4 report. Unless noted otherwise, amounts are U.S. dollars.
Business context and strategic shift
Summit is a development-stage biopharmaceutical company with no marketed products. In December 2022, it agreed to license ivonescimab (SMT112), a PD-1/VEGF bispecific antibody, from Akeso for development and commercialization in the U.S., Canada, Europe, and Japan. The deal closed on January 17, 2023, after the fiscal year-end. The company shifted its focus to oncology, ended internal development of ridinilazole, and began seeking a partner or divestiture for that program. It also plans to seek partners for preclinical antibiotic candidate SMT-738 and cease further investment in the Discuva platform.
Key financial metrics
| Metric | FY2022 / Dec. 31, 2022 | FY2021 / Dec. 31, 2021 |
|---|---|---|
| Revenue | $0.7 million | $1.8 million |
| Research and development expense | $52.0 million | $85.4 million |
| General and administrative expense | $26.7 million | $23.6 million |
| Intangible-asset impairment | $8.5 million | — |
| Other operating income | $14.4 million | $21.0 million |
| Operating loss | $72.1 million | $86.2 million |
| Net loss | $78.8 million | $88.6 million |
| Net loss per share, basic and diluted | $0.41 | $0.67 |
| Net cash used in operating activities | $41.6 million | $72.6 million |
| Cash and cash equivalents | $348.6 million | $71.8 million |
| Restricted cash | $0.3 million | — |
| Accumulated deficit | $378.3 million | $299.5 million |
Revenue came from the Eurofarma ridinilazole license arrangement; Summit reported no product-sales revenue. Margins are not a meaningful performance measure given the minimal collaboration revenue and continued development-stage losses. Year-end current assets were $656.7 million and current liabilities $38.8 million. Principal debt outstanding was $520 million at year-end ($514.3 million carrying value after debt discount), largely related-party notes.
Changes versus FY2021 and unusual items
- Net loss narrowed by $9.8 million, while operating cash outflow decreased by $31.0 million.
- R&D expense fell $33.4 million, primarily as ridinilazole clinical and manufacturing work wound down; G&A expense rose $3.1 million.
- Summit recorded an $8.5 million impairment, writing off the Discuva platform intangible asset following the oncology strategy shift.
- Other operating income declined $6.6 million, mainly because U.K. R&D tax-credit income fell by $10.7 million; BARDA income increased as closeout costs and related deferred income were recognized.
- Other expense increased to $6.7 million from $2.4 million, reflecting higher related-party note interest and foreign-exchange losses, partly offset by investment income.
Outlook, financing, and principal risks
Management expects substantial operating losses to continue and anticipates needing additional capital. It estimated that, after the post-year-end Akeso payments, the March 2023 rights offering, and repayment of $420 million of related-party notes, available resources would fund planned ivonescimab trials into the second half of 2024. The financial-statement note states that resources would cover planned trial operating costs and working capital for at least 12 months from issuance. These estimates depend on assumptions and do not remove the need for future funding.
- The Akeso license required $500 million upfront: $474.9 million cash and 10 million Summit shares. The remaining $4.5 billion of potential regulatory and commercial milestones is contingent; Akeso is also eligible for low-double-digit royalties on net sales.
- The March 2023 rights offering raised $500 million gross through 476.2 million shares; issuance costs were about $0.5 million. Proceeds funded, in part, repayment of the $400 million Duggan note. The $20 million Zanganeh note was also repaid; a $100 million Duggan note remained outstanding, with maturity extended to September 2024.
- Ivonescimab’s reported clinical data are from Akeso-led studies in China. Summit had not conducted its own ivonescimab clinical trial as of year-end; it planned to begin treating patients in its territory by Q2 2023. Further development, regulatory approval, safety, supply, and commercial success are uncertain.
- Key exposures include dependence on Akeso for licensed rights and initial supply, clinical-development risk, substantial future financing needs and dilution, competition in NSCLC, and business, regulatory, intellectual-property, and geopolitical risks associated with China.
- Robert W. Duggan beneficially owned approximately 81.8% of outstanding capital at year-end, giving him significant voting control. Stockholders had also approved a possible 1-for-5 to 1-for-10 reverse split; the board retained discretion to implement it.
The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness because Summit was a non-accelerated filer and smaller reporting company.
Most important facts for investors to verify
- Confirm post-offering cash, remaining debt, interest terms, and whether management’s stated clinical-trial runway assumptions remain valid.
- Review the full Akeso agreement for milestone triggers, royalty terms, supply obligations, termination rights, and development requirements.
- Track Summit’s own ivonescimab trial initiation, enrollment, clinical results, and regulatory plans against stated timelines.
- Assess dilution from the rights offering and license shares, and monitor any additional equity or debt financing and the status of the remaining $100 million note.
- Check the status and potential value of ridinilazole and SMT-738 partnering efforts, and any decision on the Discuva platform or reverse split.